Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2007-11-15 Capital/Financing Update
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Pharmaxis Closes Share Purchase Plan 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a media release dated 16 November 2007 from Pharmaxis announcing the closing of a Share Purchase Plan that raised $11.7 million. It details the number of shareholders participating, the number of shares to be issued, and the expected listing date of the shares. There is no financial report, earnings data, or detailed financial statements included. The document is an announcement about a capital raising event (share purchase plan) and issuance of new shares, which fits the category of Capital/Financing Update (CAP). The document length is 3414 characters, which is relatively short and consistent with a press release rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2007-11-15 English
Appendix 3B - Share Purchase Plan 10 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of ordinary shares and options by Pharmaxis Ltd, including the number of securities issued, issue price, purpose of the issue, and dates of allotment. The document references ASX (Australian Securities Exchange) rules and is a formal announcement related to capital raising activities. There is no financial performance data, management discussion, or audit information. The content fits the category of a capital or financing update, specifically about new share issuance and related securities information.
2007-11-15 English
Appendix 3B - Exercise of Employee Options 10 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements. The content details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including the number of securities, issue price, and other terms. This type of document is specifically related to capital changes and share issues rather than financial results, management changes, or other report types. It is not a full financial report but an announcement of a capital change event. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a brief announcement but a formal filing of a capital change.
2007-11-08 English
Completion of FDA Special Protocol Assistance - CF 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 08 November 2007 from Pharmaxis announcing the completion of a Special Protocol Assessment (SPA) with the U.S. FDA for a Phase 3 clinical trial design of their drug Bronchitol. It discusses the trial design, regulatory status, and development pipeline but does not contain financial statements, detailed financial analysis, or comprehensive company performance data. It is a regulatory update about clinical trial progress and FDA agreement, not a financial report or earnings release. The document is a public announcement of a regulatory milestone rather than a detailed report or filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2007-11-07 English
Aridol to be evaluated in major US asthma study 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 08 November 2007 from Pharmaxis Ltd announcing that their product Aridol will be evaluated in a major US asthma study. It discusses the study details, regulatory filings planned (FDA marketing application in Q1 2008), and provides background on the product and company. There are no financial statements, earnings data, or detailed financial analysis. The document is a corporate announcement about a clinical study and regulatory progress, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention a report being published or attached. It is not a call transcript, management report, or any other financial filing. The best fit is Regulatory Filings (RNS) as a general regulatory announcement and corporate update that does not fit other categories.
2007-11-07 English
Amended Constitution 45 pages ?Kb
Governance Information Classification · 100% confidence The document is titled 'Constitution' and contains detailed provisions about the company's shares, share capital, calls, liens, forfeiture, and related corporate governance matters. It is a legal and governance document outlining the internal rules and regulations of the company rather than a financial report, announcement, or presentation. There is no indication of financial statements, audit information, earnings data, or shareholder meeting materials. The content aligns with governance practices and company internal rules. Therefore, the document best fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full constitution text, not a brief announcement or summary.
2007-11-06 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.